Virios rises on plans to advance lead candidate to late-stage study

Dogwood Therapeutics

09/08/2023 12:53

** Shares of therapy developer Virios Therapeutics  VIRI.O 
rise 10.06% to $1.86 premarket
    ** Co plans to initiate proposed pharmacokinetic and food
effect study of its lead candidate IMC-1 this year after FDA's
feedback, while concurrently resubmitting a final late-stage
program outline and study protocols for FDA review
    ** Following completion of the study, the goal will be to
begin enrollment in the first late-stage study for safety and
efficacy for fibromyalgia treatment in mid-2024 -VIRI
    ** Fibromyalgia is a chronic disorder that causes pain and
tenderness throughout the body as well as fatigue and trouble
sleeping
    ** Up to last close, stock up ~616% YTD

 (Reporting by Sriparna Roy)
 ((sriparna.roy@thomsonreuters.com))